$CGNT (Cogentix Medical, Inc.)

$CGNT {{ '2016-09-08T12:12:06+0000' | timeago}} • Announcement

The terms of transaction call for Accelmed to have the right to nominate 2 members to the $CGNT BoD, which currently has 6 members. One of these directors would be Accelmed Co-Founder Uri Geiger who will become Chair of $CGNT Board.

$CSX {{ '2018-01-17T20:31:04+0000' | timeago}} • Infographic

$CSX CSX Corp Earnings AlphaGraphic: Q4 2017 highlights

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$CSX {{ '2018-01-17T12:49:51+0000' | timeago}} • Webcast

$CSX expects a step-down in the operating ratio every year for the next three years. The company expects CapEx to be $1.6Bil down significantly from FY17.

$CSX {{ '2018-01-17T12:34:04+0000' | timeago}} • Webcast

For FY18, $CSX expects revenue to be up slightly with merchandising intermodal services offerings much better than last year. The company expects to see "more favourable results" in the second half of the year.

$CSX {{ '2018-01-16T21:31:18+0000' | timeago}} • Announcement

Even as revenue slipped 6% to $2.86Bil, $CSX saw earnings jump almost 9 times to $4.14Bil or $4.62 per diluted share in 4Q17 from last year's $458MM or $0.49 per share. This was due to a $3.16Bil income tax benefit in the quarter.

$INFO {{ '2018-01-16T20:28:30+0000' | timeago}} • Infographic

$INFO IHS Markit Ltd. Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CSX {{ '2018-01-08T21:10:07+0000' | timeago}} • Announcement

$CSX announced that Edmond L. Harris has been named executive vice president of operations, effective immediately.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$INFO {{ '2018-01-03T13:30:22+0000' | timeago}} • Announcement

$INFO appointed Lord Browne of Madingley and Nicoletta Giadrossi as new directors of the company. Also, Lance Uggla, the company’s president and COO, became chairman and CEO of $INFO on Jan. 1, 2018, following the retirement of chairman and CEO Jerre Stead on Dec. 31, 2017.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CSX {{ '2017-12-26T11:05:59+0000' | timeago}} • Announcement

$CSX named James Foote as the company’s President and CEO, effective Dec. 22, 2017. Foote was named acting CEO on Dec. 14, 2017 after Hunter Harrison was placed on medical leave. James Foote will also join the company's BoD.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$RHT {{ '2017-12-20T14:24:30+0000' | timeago}} • Announcement

Open source software provider $RHT, which recently announced partnerships with $BABA and SoftBank, saw a surge in its 3Q18 profit, driven by higher subscriptions and higher revenue. Profit surged 49% to $101.3MM or $0.54 per share, up from $68MM or $0.37 a year earlier. Revenue rose 22% to $748MM. On an adjusted basis, $RHT earned $0.73 per share.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

Recent Transcripts

CSX (CSX Corp.)
Tuesday, January 16 2018 - 9:30pm
INFO (IHS Markit Ltd.)
Tuesday, January 16 2018 - 1:00pm
AVGR (Avinger, Inc.)
Thursday, November 9 2017 - 9:30pm
APPS (Digital Turbine, Inc.)
Tuesday, November 7 2017 - 9:30pm
CGNT (Cogentix Medical, Inc.)
Tuesday, November 7 2017 - 9:30pm
BABA (Alibaba Group Holding Limited)
Thursday, November 2 2017 - 11:30am
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
CSX (CSX Corp.)
Tuesday, October 17 2017 - 12:30pm
INFO (IHS Markit Ltd.)
Tuesday, September 26 2017 - 12:00pm
BABA (Alibaba Group Holding Limited)
Thursday, August 17 2017 - 11:30am
AVGR (Avinger, Inc.)
Tuesday, August 8 2017 - 8:30pm
APPS (Digital Turbine, Inc.)
Monday, August 7 2017 - 8:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
CGNT (Cogentix Medical, Inc.)
Tuesday, August 1 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm

AlphaGraphics you may like